Pipeline Insight: Depression - Novel therapies key to market penetration

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2003-09-15

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Introduction
With the global antidepressant market valued at $16.6 billion in 2002, drugs for the treatment of depression have historically provided huge returns on investment. However, several of the leading brands are expecting patent expiries over the next five years. New strategies are needed to prevent a decline in the antidepressant market.

Scope


Highlights
Duloxetine, Eli Lilly's follow-up compound to Prozac, is set to become the next drug to enter the antidepressant market. However, convincing physicians that it is superior to Wyeth's Effexor may prove challenging. Lilly needs to position duloxetine as an alternative first-line therapy to selective serotonin reuptake inhibitors (SSRIs).

Merck's NK1 receptor antagonist, aprepitant, is expected to be the first drug from another completely new class of antidepressants to hit the market. Its launch in 2006 will precipitate an influx of similar compounds to the market, presenting a major threat to the leading position of first-line therapy SSRIs.

Why you should buy this report

Table of Contents

Other users found this report page using the following search terms: depression Antidepressants major depression depression pipeline market aprepitant penetration antidepressant novel therapies phase ectris

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.